AtriCure (ATRC) Misses Q4 EPS by 4c

AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $52.9 million versus the consensus estimate of $51.56 million.

GUIDANCE:

AtriCure sees FY2019 revenue of $220-228 million, versus the consensus of $223.45 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Dare Bioscience (DARE) Tops Q2 EPS by 11c
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c